Want to see AU:IIQ full AI Analyst Report?
Top Page
Inoviq Ltd
(Sydney:IIQ)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.28
▼(-31.00% Downside)
Action:Downgraded
Date:07/02/26
The score is primarily constrained by weak financial performance (declining revenue, negative profitability, and negative operating/free cash flow). Technicals add further pressure with the stock trading below all major moving averages, while valuation signals are limited due to a negative P/E and no dividend yield data.
Positive Factors
Low financial leverage
Very low debt-to-equity provides durable financial flexibility: it reduces insolvency risk, preserves borrowing capacity for R&D or commercialization, and allows the firm to pursue partnerships or licensing without immediate refinancing pressure. This structural strength supports multi-month strategic options.
Negative Factors
Revenue decline and negative margins
Sustained revenue decline combined with negative gross and operating margins signals weak product-market fit or pricing/scale issues. Over a 2–6 month horizon, this undermines reinvestment capacity, strains commercial rollouts, and can necessitate structural changes to strategy or cost base to restore profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low debt-to-equity provides durable financial flexibility: it reduces insolvency risk, preserves borrowing capacity for R&D or commercialization, and allows the firm to pursue partnerships or licensing without immediate refinancing pressure. This structural strength supports multi-month strategic options.
Read all positive factors
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$38.01M
Dividend YieldN/A
Average Volume (3M)196.06K
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue Growth4.66%
EPS Growth12.39%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$1.65M
Inoviq Ltd Business Overview & Revenue Model
Company Description
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current p...
How the Company Makes Money
Inoviq’s revenue model is based on commercialising its technologies via a mix of product/service sales and partnering/licensing arrangements tied to its diagnostics and research platforms. Key revenue streams typically include: (1) sales of resear...
Inoviq Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22M | 1.82M | 535.12K | 398.19K | 276.75K | 1.27M |
| Gross Profit | -583.05K | -1.56M | 454.11K | -1.04M | -1.88M | -2.21M |
| EBITDA | -7.87M | -6.16M | -6.34M | -9.32M | -19.39M | -6.05M |
| Net Income | -7.24M | -6.93M | -6.55M | -8.97M | -18.20M | -11.15M |
Balance Sheet | ||||||
| Total Assets | 24.52M | 18.46M | 21.71M | 21.51M | 30.78M | 33.52M |
| Cash, Cash Equivalents and Short-Term Investments | 13.80M | 6.52M | 9.23M | 7.81M | 15.39M | 5.00M |
| Total Debt | 270.31K | 376.19K | 776.54K | 730.71K | 998.69K | 1.26M |
| Total Liabilities | 2.26M | 1.74M | 1.72M | 1.89M | 2.49M | 4.46M |
| Stockholders Equity | 22.26M | 16.71M | 19.99M | 19.62M | 28.29M | 29.06M |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.77M | -4.50M | -7.32M | -6.47M | -6.05M |
| Operating Cash Flow | -4.99M | -4.66M | -4.32M | -7.02M | -6.06M | -5.26M |
| Investing Cash Flow | -88.12K | -104.00K | -174.34K | -292.27K | -411.90K | 2.64M |
| Financing Cash Flow | 9.41M | 2.05M | 5.91M | -267.98K | 16.87M | 286.48K |
Inoviq Ltd Technical Analysis
Negative
0.40
Price Trends
0.36
Negative
0.35
Negative
0.36
Negative
Market Momentum
0.02
Positive
37.68
Neutral
35.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.36, and above the 200-day MA of 0.36, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 37.68 is Neutral, neither overbought nor oversold. The STOCH value of 35.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IIQ.
Inoviq Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$99.16M | -5.95 | -164.12% | ― | -14.85% | -41.04% | |
41 Neutral | AU$36.41M | -4.63 | -476.27% | ― | ― | -142.39% | |
40 Underperform | AU$38.01M | -4.31 | -37.14% | ― | 4.66% | 12.39% | |
40 Underperform | AU$14.76M | -1.31 | -23.93% | ― | 9.69% | 52.31% | |
39 Underperform | AU$26.55M | -3.62 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:IIQ
Inoviq Ltd
0.27
-0.10
-27.03%
AU:BDX
BCAL Diagnostics Limited
0.07
<0.01
2.86%
AU:RHY
Rhythm Biosciences Ltd.
0.10
0.04
66.67%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.11
0.08
250.00%
AU:GSS
Genetic Signatures Ltd.
0.07
-0.30
-82.19%
Inoviq Ltd Corporate Events
INOVIQ boosts EXO-OC accuracy but halts flawed ovarian cancer study
Jul 1, 2026
INOVIQ has enhanced the algorithm underpinning its EXO-OC ovarian cancer blood test, reporting improved diagnostic performance with over 92% sensitivity for both early-stage and all-stage disease at high specificity on its initial 500-sample datas...
Inoviq Seeks Trading Halt Ahead of Key EXO-OC Clinical Study Results
Jun 28, 2026
Inoviq Ltd, an ASX-listed medical diagnostics company focused on oncology-related blood tests such as its EXO-OC assay, is progressing clinical validation of its product pipeline to strengthen its position in the biotechnology sector. The company&...
Inoviq Options Lapse Removes 1.1 Million Potential Shares
Jun 26, 2026
Inoviq Ltd has notified the market that 1,100,000 options, classified under the ASX security code IIQAE and expiring on various dates at various prices, have lapsed. The options ceased due to the non-satisfaction or incapacity of conditions attach...
INOVIQ posts strong ovarian cancer data for off-the-shelf CAR-exosome therapy
Jun 24, 2026
INOVIQ reported positive in vitro proof-of-concept data showing its CAR-exosome platform achieved rapid tumour-killing in multiple ovarian cancer cell lines, eliminating up to 90% of cells within 48 hours when targeting CA125 and over 80% when tar...
Inoviq links share price jump to research note as key EXO-OC study nears milestone
Jun 17, 2026
Inoviq has responded to an ASX price query after its shares rose from A$0.295 to A$0.365 in a single day, stating it is not aware of any undisclosed information that could explain the trading activity. The company instead pointed to a third-party ...
INOVIQ Director Peter Gunzburg Lifts Indirect Shareholding
May 26, 2026
INOVIQ Limited has reported a change in the indirect holdings of director Peter Gunzburg, who increased his stake in the company through associated entities. The transactions, executed via on-market purchases on 22 and 25 May 2026, added 30,000 or...
Inoviq Advances Ovarian Cancer Test and CAR-Exosome Pipeline as Cash Reserves Support Growth
Apr 27, 2026
Inoviq reported progress across its exosome-based oncology portfolio, with its flagship EXO-OC ovarian cancer screening test advancing through an expanded retrospective clinical study of around 2,000 plasma samples, and cancer-control group analys...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.